Remarkable Long-Term Survival in High-Grade Glioma Patients
High-grade gliomas are among the most aggressive primary brain tumors. Standard treatment typically includes surgery, radiation therapy, and chemotherapy. Even with intensive care, long-term survival has historically been limited, which is why continued clinical research remains critical.
A 2025 peer-reviewed publication in the Journal of Neurology & Neuroscience reports unusually long survival in a group of patients with non-glioblastoma high-grade gliomas treated in Phase II clinical studies with Antineoplastons A10 and AS2-1 at Burzynski Clinic in Houston, Texas.
The publication documents outcomes in 61 patients who survived more than five years following diagnosis. Within that group:
- 23 patients survived longer than 12 years
- 8 patients survived longer than 20 years
- 2 patients survived more than 30 years
- 1 patient surpassed 33 years of overall survival
These patients were treated between 1992 and 2004 under structured Phase II clinical protocols and were followed long term.
“When we see survival outcomes extending decades beyond diagnosis, it reinforces the importance of continuing to investigate therapies that target the biology of these tumors more precisely,” - Dr. Stanislaw Burzynski.
What Makes High-Grade Gliomas So Difficult to Treat?
High-grade gliomas grow rapidly and often infiltrate surrounding brain tissue. Even after surgical removal, microscopic tumor cells can remain, contributing to recurrence. Conventional therapies may slow progression but are frequently associated with significant side effects, including neurological impairment, fatigue, and long-term cognitive changes.
Their location within critical areas of the brain can further limit how aggressively surgeons and radiation oncologists can treat the tumor without affecting essential functions such as speech, movement, or memory. In addition, the biological heterogeneity of these tumors means that different cells within the same tumor may respond differently to treatment.
Recurrence is common, and treatment options for recurrent disease can be limited. For this reason, research continues to explore targeted approaches designed to address tumor biology while minimizing long-term toxicity.
How Were Antineoplastons Used in These Studies?
In the reported Phase II studies, patients received intravenous Antineoplastons A10 and AS2-1 administered according to structured clinical protocols, with dosing gradually increased to reach maximum tolerated levels.
Some patients later transitioned to oral maintenance therapy after completing intravenous treatment. Treatment response was monitored through serial MRI imaging at defined intervals and evaluated using standardized objective response criteria to assess tumor changes over time.
Among the long-term survivors:
- Complete responses were documented in multiple patients
- Partial responses and stable disease were observed
- Four patients experienced six serious adverse events possibly related to therapy, and all fully recovered
- No long-term adverse sequelae related to Antineoplastons were reported in surviving patients
Radiologic findings were reviewed and confirmed by independent neuroradiologists not affiliated with the clinic, providing additional verification of imaging-based outcomes.
The Role of Molecular and Genomic Research
The study also discusses the evolving importance of molecular classification and genomic profiling in high-grade glioma management. Advances in tumor classification now incorporate genetic and molecular markers that help define tumor subtype, expected behavior, and potential treatment response. Modern classifications recognize that tumors once grouped together under a single diagnosis may behave very differently based on their underlying genetic drivers.
Molecular analysis can evaluate alterations in genes associated with tumor growth, resistance, and progression. These insights may help guide more individualized treatment planning by identifying biological pathways that are active within a patient’s tumor.
The publication describes Antineoplastons as influencing gene expression patterns involved in cell cycle regulation and tumor growth. According to the authors, this mechanism may include:
- Modulation of oncogenes and tumor suppressor genes
- Interference with pathways involved in uncontrolled cell proliferation
- Effects on signaling pathways linked to tumor survival
- Potential influence on multiple genomic aberrations identified in tumor analysis
As cancer treatment becomes increasingly personalized, integrating molecular data into therapeutic planning remains an important area of investigation. Continued research aims to better understand how genomic profiling can help match patients with targeted strategies that align with the biological characteristics of their specific tumor.
Why These Findings Matter
Long-term survival extending beyond 20 or 30 years is uncommon in high-grade glioma. The documentation of such outcomes in a defined patient cohort contributes additional data to the scientific literature and supports continued clinical evaluation of innovative approaches.
For patients and families facing a high-grade glioma diagnosis, ongoing research provides important information that may inform conversations with their healthcare team. Burzynski Clinic continues to focus on research-driven, personalized treatment strategies while contributing findings to the broader oncology community.
*Educational purposes only. Not medical advice.